Myeloproliferative Neoplasms | Specialty

Dr. Bradley on the Utility of Ruxolitinib in Myelofibrosis and Polycythemia Vera

April 28th 2020

Terrence J. Bradley, MD, discusses the utility of ruxolitinib (Jakafi) in myelofibrosis and polycythemia vera.

Dr. Fleur-Lominy on the Current Sequencing Strategy in MPNs

April 28th 2020

Shella Saint Fleur-Lominy, MD, PhD, discusses the current sequencing strategy in the treatment of patients with myeloproliferative neiplasms.

Dr. Nagalla on Efforts to Predict Risk of Thrombosis in Patients With MPNs

April 25th 2020

Dr. Bradley on the Challenges Faced in MPNs

April 25th 2020

Terrence J. Bradley, MD, discusses the challenges of treating patients with myeloproliferative neoplasms.

Dr. Cortes on the Challenges of Using Ruxolitinib in MPNs

April 24th 2020

Jorge E. Cortes, MD, director of the Georgia Cancer Center at Augusta University, discusses the challenges of using ruxolitinib (Jakafi) in patients with myeloproliferative neoplasms (MPNs).

Dr. Snyder on How Ruxolitinib and Fedratinib May Pave the Way to Transplant in Myelofibrosis

April 23rd 2020

David S. Snyder, MD, discusses how ruxolitinib and fedratinib may be used to pave the way toward transplant for patients with myelofibrosis.

Dr. Rossetti on the Utility of JAK Inhibitors in MPNs

April 22nd 2020

James M. Rossetti, DO, discusses the utility of JAK inhibitors in myeloproliferative neoplasms.

Dr. Michaelis on Potential Combination Strategies With Ruxolitinib in Myelofibrosis

April 22nd 2020

Laura C. Michaelis, MD, discusses potential combination strategies with ruxolitinib in myelofibrosis.

Dr. Mesa on the Utility of Ruxolitinib Versus Fedratinib in Myelofibrosis

April 21st 2020

Ruben Mesa, MD, discusses the use of ruxolitinib versus fedratinib in patients with myelofibrosis and baseline thrombocytopenia.

Dr. Schmaier on Managing Cancer-Associated Thrombosis

April 17th 2020

Alvin H. Schmaier, MD, professor in the Department of Medicine and the Department of Pathology at Case Western Reserve University School of Medicine, discusses the management of patients with cancer-associated thrombosis.

Dr. Bradley on Evolving Therapeutic Strategies in MPNs

April 17th 2020

Terrence J. Bradley, MD, discusses the evolution of therapeutic strategies in myeloproliferative neoplasms.

Mesa Provides Perspective on Diagnosis and Treatment in Essential Thrombocythemia

April 15th 2020

Ruben A. Mesa, MD, discusses the current state of ET treatment, the challenges of diagnosing the disease, and available educational resources for healthcare providers and patients.

Managing Treatment Toxicity in CML and MPNs

April 14th 2020

Jorge E. Cortes, MD, discusses managing treatment toxicities to optimize therapeutic outcomes in patients with CML and MPNs.

Dr. Pemmaraju on the Need for Collaboration in Myelofibrosis

April 14th 2020

Naveen Pemmaraju, MD, discusses the need for collaboration when diagnosing and treating patients with myelofibrosis.

Dr. Mesa on Unanswered Questions Regarding JAK Inhibitors in Myelofibrosis

April 11th 2020

Ruben Mesa, MD, discusses unanswered questions regarding JAK inhibitors in myelofibrosis.

Dr. Rossetti on the Fast Track Designation of Momelotinib in Myelofibrosis

April 10th 2020

James M. Rossetti, DO, discusses the FDA’s decision to grant momelotinib a fast track designation for use in patients with intermediate- or high-risk myelofibrosis who previously received a JAK inhibitor.

Dr. Michaelis on Unanswered Questions in Myelofibrosis Treatment

April 10th 2020

Laura C. Michaelis, MD, discusses the direction of future myelofibrosis research.

Dr. Snyder on Tools to Improve Use of Allogeneic Stem Cell Transplant in Myelofibrosis

April 8th 2020

David S. Snyder, MD, discusses tools to improve the use of allogeneic stem cell transplant in myelofibrosis.

Dr. Jain on High-Risk Mutations in Myelofibrosis

April 8th 2020

Tania Jain, MBBS, sheds light on the mutations that confer worse prognosis in myelofibrosis.

Dr. Saint Fleur-Lominy on Remaining Challenges in Myelofibrosis

April 8th 2020

Shella Saint Fleur-Lominy, MD, PhD, discusses remaining challenges in myelofibrosis.